🇺🇸 Tocilizumab(400mg) in United States

15 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 15

Most-reported reactions

1. Alanine Aminotransferase Increased — 3 reports (20%)
2. Oxygen Saturation Decreased — 2 reports (13.33%)
3. Sars-Cov-2 Test Positive — 2 reports (13.33%)
4. Transaminases Increased — 2 reports (13.33%)
5. Acute Respiratory Failure — 1 report (6.67%)
6. Aspartate Aminotransferase Increased — 1 report (6.67%)
7. Blood Bilirubin Increased — 1 report (6.67%)
8. Blood Creatinine Increased — 1 report (6.67%)
9. Citrobacter Infection — 1 report (6.67%)
10. Crystal Nephropathy — 1 report (6.67%)

Source database →

Frequently asked questions

Is Tocilizumab(400mg) approved in United States?

Tocilizumab(400mg) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Tocilizumab(400mg) in United States?

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University is the originator. The local marketing authorisation holder may differ — check the official source linked above.